Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study
Europace · 02.06.2026 · 28 (6)
DOI: 10.1093/europace/euag151 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Europace, online erschienen am 30.06.2026. Verfasst von Bjarke Sihm Stender und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, Aarhus DK-8200, Denmark. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Stroke, Factor Xa Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Life-long direct oral anticoagulant (DOAC) therapy is recommended after catheter ablation for atrial fibrillation (AF) in high-risk patients (CHA2DS2-VA≥2). Long-term DOAC compliance is crucial for effective stroke prevention. This study seeks to evaluate long-term compliance measured by adherence and persistence to DOAC therapy following first-time catheter abltation for AF. Methods and results All Danish patients undergoing first-time catheter ablation between 2017 and 2024 were identified through Danish registries. Patients were stratified by CHA2DS2-VA score 0, 1, and ≥2. Primary outcomes were adherence and persistence to DOAC therapy at 1, 2, and 3 years after first-time catheter ablation. Adherence was defined as the proportion of days covered (PDC) ≥80%. Persistence was assessed as the proportion of patients covered based on the most recent pharmacy redemption before specific time points, given a 20% grace period. A total of 13 438 patients (32.1% female) were included. At 3 years post-ablation, the proportion of adherent patients with CHA2DS2-VA ≥2 (n = 7322) was 87.6% [95% cinfidence interval (CI): 86.8–88.4]. Applying a sensitivity analysis with a PDC ≥90% threshold, the proportion was 78.8% (95% CI: 77.8–79.8%). Persistence was 73.0% (95% CI: 71.6–74.4%) at 3 years. Rates of thromboembolic outcomes were low with a total incidence rate of the combined outcome of ischaemic stroke, transient ischaemic attack and systemic embolism at 6.6 per 1000 person-years (95% CI: 5.8–7.4). The incidence of major bleeding was found at 7.1 per 1000 person-years (95% CI: 6.3–8.0) for the combined cohort. Conclusion While adherence to DOAC therapy was acceptable in patients with CHA2DS2-VA≥2, persistence declined over time and more than 20% were non-persistent by 3 years. Efforts to improve effective long-term stroke prevention may be warranted. Unstructured abstract Life-long direct oral anticoagulant (DOAC) therapy is recommended after catheter ablation for atrial fibrillation in high-risk patients (CHA2DS2-VA≥2). Adherence and persistence to DOAC is crucial for effective stroke prevention. Danish patients undergoing first-time catheter ablation between 2017 and 2024 were identified through registries. A total of 13 438 patients were included. At 3 years post-ablation, the proportion of adherent and persistent patients with CHA2DS2-VA ≥2 (n = 7322) was 87.6% and 73.0%, respectively. Adherence to DOAC was acceptable in patients with CHA2DS2-VA≥2. More than 20% of patients were non-persistent by 3 years. Efforts to improve effective long-term stroke prevention may be warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, Aarhus DK-8200, Denmark.
- Department of Cardiology, Regional Hospital Gødstrup, Herning, Denmark.
- Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
ORCID-Profile: Bjarke Sihm Stender, Victor Kjær Eskildsen, Anders Kramer, Kasper Korsholm, Kasper Bonnesen, Morten Schmidt, Mads Brix Kronborg, Jens Erik Nielsen-Kudsk
Zitieren
APA
Stender, B. S., Eskildsen, V. K., Kramer, A., Poulsen, M. H., Korsholm, K., Bonnesen, K., Schmidt, M., Kronborg, M. B., & Nielsen-Kudsk, J. E. (2026). Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study. Europace, 28(6). https://doi.org/10.1093/europace/euag151
Vancouver
Stender BS, Eskildsen VK, Kramer A, Poulsen MH, Korsholm K, Bonnesen K, et al. Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study. Europace. 2026;28(6). doi:10.1093/europace/euag151
BibTeX
@article{Stender2026,
author = {Stender, Bjarke Sihm and Eskildsen, Victor Kjær and Kramer, Anders and Poulsen, Maja Hellfritzsch and Korsholm, Kasper and Bonnesen, Kasper and Schmidt, Morten and Kronborg, Mads Brix and Nielsen-Kudsk, Jens Erik},
title = {Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study},
journal = {Europace},
year = {2026},
volume = {28},
number = {6},
doi = {10.1093/europace/euag151}
}
EUVIMED